Genenta Science S.p.A. (GNTA) 6-K 29 Oct 24 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2024
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41115
Entity Registrant Name	GENENTA SCIENCE S.P.A.
Entity Central Index Key	0001838716
Entity Address, Address Line One	Via Olgettina No. 58
Entity Address, City or Town	Milan
Entity Address, Country	IT
Entity Address, Postal Zip Code	20132

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - EUR (€)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating expenses
Research and development	€ 2,040,390	€ 3,921,802
General and administrative	2,477,978	2,878,373
Total operating expenses	4,518,368	6,800,175
Loss from operations	(4,518,368)	(6,800,175)
Other income (expense)
Other income	180,781	114,992
Finance income	145,290	77,999
Net exchange rate gain (loss)	153,791	(152,041)
Total other income, net	479,862	40,950
Loss before income taxes	(4,038,506)	(6,759,225)
Income tax benefit (expense)
Net loss	€ (4,038,506)	€ (6,759,225)
Net loss per share - basic	€ (0.22)	€ (0.37)
Weighted average number of shares outstanding - basic	18,256,622	18,216,858
Weighted average number of shares outstanding - diluted	18,256,622	18,216,858
Other comprehensive income (loss)
Total change of marketable debt securities	€ (64,288)
Change in foreign currency translation	(16,081)
Total other comprehensive income	(80,369)
Comprehensive loss	€ (4,118,875)	€ (6,759,225)

Consolidated Balance Sheets

Consolidated Balance Sheets - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	€ 6,187,966	€ 3,691,420
Marketable securities	10,718,210	15,084,284
Prepaid expenses and other current assets	1,663,297	2,480,554
Total current assets	18,569,473	21,256,258
Non-current assets
Fixed assets, net	62,714	82,977
Total non-current assets	447,734	1,090,887
Total assets	19,017,207	22,347,145
Current liabilities
Other current liabilities	441,296	255,062
Total current liabilities	1,995,823	1,735,639
Non-current liabilities
Other non current liabilities	7,981	14,594
Retirement benefit obligation	196,368	164,655
Total long-term liabilities	204,349	179,249
Commitments and contingencies
Shareholders’ equity
Ordinary shares, no par value, 59,700,000 shares authorized and 18,289,866 and 18,216,958 shares issued and outstanding, respectively	67,847,793	67,344,140
Accumulated deficit	(51,181,531)	(47,143,025)
Accumulated other comprehensive income	150,773	231,142
Total shareholders’ equity	16,817,035	20,432,257
Total liabilities and shareholders’ equity	19,017,207	22,347,145
Nonrelated Party [Member]
Non-current assets
Other non-current assets	381,670	1,004,560
Current liabilities
Accounts payable	405,846	294,975
Accrued expenses	260,051	153,136
Related Party [Member]
Non-current assets
Other non-current assets	3,350	3,350
Current liabilities
Accounts payable	189,762	170,888
Accrued expenses	€ 698,868	€ 861,578

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - € / shares	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	€ 0	€ 0	€ 0
Common Stock, Shares Authorized	59,700,000	59,700,000
Common Stock, Shares, Outstanding	18,289,866	18,216,958		18,216,858	18,216,858

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - EUR (€)	Common Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2022	€ 66,603,725	€ (35,465,559)		€ 31,138,166
Balance, shares at Dec. 31, 2022	18,216,858
Share-based compensation	€ 415,433			415,433
Cumulative translation adjustment		9,716		9,716
Net loss		(6,759,225)		(6,759,225)
Balance at Jun. 30, 2023	€ 67,019,158	(42,215,068)		24,804,090
Balance, shares at Jun. 30, 2023	18,216,858
Share-based compensation	€ 324,451			324,451
Cumulative translation adjustment		(9,716)		(9,716)
Net loss		(4,886,230)		(4,886,230)
Capital increase ATM program	€ 531			531
Capital increase ATM program, shares	100
Other comprehensive income		(32,011)	231,142	199,131
Balance at Dec. 31, 2023	€ 67,344,140	(47,143,025)	231,142	20,432,257
Balance, shares at Dec. 31, 2023	18,216,958
Share-based compensation	€ 232,768			232,768
Cumulative translation adjustment
Net loss		(4,038,506)		(4,038,506)
Capital increase ATM program	€ 270,885			270,885
Capital increase ATM program, shares	72,908
Other comprehensive income			(80,369)	(80,369)
Balance at Jun. 30, 2024	€ 67,847,793	€ (51,181,531)	€ 150,773	€ 16,817,035
Balance, shares at Jun. 30, 2024	18,289,866

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - EUR (€)	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Cash flows from operating activities
Net loss	€ (4,038,506)	€ (4,886,230)	€ (6,759,225)
Adjustments to reconcile net loss to net cash used in operating activities:
Foreign exchange adjustment		(9,716)	9,716
Depreciation expense	22,132		21,143
Retirement benefit obligation	31,713		40,486
Share-based compensation	232,768		415,433
Net gain (loss) on purchase of marketable securities			(9,517)
Changes in operating assets and liabilities
Prepaid expenses and other current assets	817,258		(377,721)
Other non-current assets	622,890		(502,229)
Accounts payable	110,871		(692,780)
Accounts payable - related party	18,874		(21,768)
Accrued expenses	106,915		245,976
Accrued expenses - related party	(162,710)		143,174
Other current liabilities	186,234		(86,603)
Other non-current liabilities	(6,613)		(6,214)
Net cash used in operating activities	(2,058,174)		(7,580,129)
Cash flows from investing activities
Purchases of marketable securities	(8,998,556)		(9,989,030)
Proceeds from maturities of marketable securities	13,300,341
Purchases of fixed assets	(1,869)		(12,437)
Net cash (used in) provided by investing activities	4,299,916		(10,001,467)
Cash flows from financing activities
Proceeds from ATM program	270,885
Net cash provided by financing activities	270,885
Effect of exchange rate changes	(16,081)
Net increase (decrease) in cash and cash equivalents	2,496,546		(17,581,596)
Cash and cash equivalents at beginning of period	3,691,420	12,213,260	29,794,856
Cash and cash equivalents at end of period	€ 6,187,966	€ 3,691,420	€ 12,213,260

Nature of business and history

Nature of business and history	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business and history	1. Nature of business and history Genenta Science S.p.A. (the “Company” or “Genenta”) – formerly Genenta Science S.r.l., a “società a responsabilità limitata” (“S.r.l.”), which is similar to a limited liability company in the United States (“U.S.”) converted to a “società per azioni” (“S.p.A.”), an Italian corporation in June 2021, which is similar to a C corporation in the U.S. The Company was founded in Milan, Italy by San Raffaele Hospital (“OSR”), Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner, and was incorporated in July 2014. On May 20, 2021, the quotaholders (owners of the Company) resolved that the Company convert from an S.r.l. to an S.p.A. and determined that the outstanding quota be converted to 15 On December 17, 2021, the Company completed an initial public offering (“IPO”) of its shares. The shares began trading on the Nasdaq Stock Capital Market (“Nasdaq”) on December 15, 2021. Through the IPO, 3,120,114 new ordinary shares with no par value were issued. 720,114 ordinary shares were subscribed by the Company’s existing shareholders through a reserved offering, while 2,400,000 American Depository Shares (“ADSs”), each representing one of the Company’s ordinary shares, were offered to the public 96,744 ADSs. The total number of shares outstanding resulting at December 31, 2021 was 18,216,858 . Through the IPO, approximately € 29 million was raised, net of listing costs (approximately € 3.9 million). On May 12, 2023, the Company filed with the Securities and Exchange Commission (the “SEC”) a shelf registration statement that was subsequently declared effective on May 24, 2023. It permits the Company to sell from time-to-time ordinary shares, including ordinary shares represented by ADSs, or rights to subscribe for ordinary shares or ordinary shares represented by ADSs in one or more offerings in amounts, at prices, and on the terms that the Company will determine at the time of offering for aggregate gross sale proceeds of up to $ 100 In June 2023, the Company’s shareholders reduced the number of directors from seven (7) to five (5). In July 2023, the Company issued 100 531 582 18,216,958 SM In March 2024, the Company issued 72,908 ADSs for net proceeds of approximately € 270,885 (or $ 293,328 ), bringing the total number of ordinary 18,289,866 , pursuant to the Prior Sales Agreement. On March 28, 2024, the Company and Cantor mutually agreed to terminate the Prior On April 26, 2024, the Company entered into an ATM Sales Agreement (the “Current Sales Agreement”) with Capital One Securities, Inc. and Virtu Americas LLC (the “Sales Agents”), pursuant to which the Company may offer and sell ADSs, for an aggregate offering price of up to $ 16,362,816 In May 2024, the Company’s shareholders approved an amendment of article 9 of the Company’s Bylaws, introducing increased voting rights by introducing a mechanism whereby each ordinary share owned by the same subject (either an entity or an individual) for a continuous period of not less than twenty-four months entitles the holder to a double vote and therefore to an increase from one to two votes per share. In addition, a further vote is attributed at the end of each twelve-month period, following the first vesting period of twenty-four months, in which the ordinary share has belonged to the same entity or individual, Genenta is an early-stage company developing first-in-class cell and gene therapies to address unmet medical needs in cancerous solid tumors. The Company is initially developing its clinical leading product, Temferon™, to treat glioblastoma multiforme (“GBM”), a solid tumor affecting the brain. The Company intends to continue its clinical trials in Italy, and eventually start a clinical trial in Europe and the U.S. to study Temferon™ in other cancers. In June 2023, the Company’s Board of Directors (the “Board”) selected Renal Cell Cancer (“RCC”) as the second solid tumor indication for Temferon. The Company is currently finalizing The Company is subject to risks and uncertainties common to early-stage clinical companies in the life-science and biotechnology industries, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new competing products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The clinical product candidates currently under development will require significant additional research and development efforts, including regulatory approval and clinical testing prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales and profit from operations. Liquidity and risks The Company has incurred losses since its inception, including a net loss of € 4.0 million and € 6.8 million for the six months ended June 30, 2024, and June 30, 2023, respectively. In addition, at June 30, 2024, the Company had an accumulated deficit of € 51.2 million. The Company has primarily funded these losses through the proceeds from sales of convertible debt and equity quotas, before the Company’s conversion into an S.p.A., and then through the proceeds from its IPO. The Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future. In addition, the Company expects that its existing cash and cash equivalents on hand of € 6.2 million, together with the other short-term 10.7 million as of June 30, 2024 will be sufficient to fund current planned operations and capital expenditure requirements for at least the next twelve months. However, the as and when needed ability to continue as a The Company’s business model, typical of biotechnology companies developing new therapeutic products that have not reached a balanced income and financial position, features negative cash flows. This is because, at this stage, costs must be borne in relation to services and personnel, directly connected to research and development activities, and return for these activities is not certain and, in any case, it is expected in future years. Based on the accounting policies adopted, requiring full recognition of research and development costs in the statement of operations and comprehensive loss in the year they are incurred, the Company has reported a loss since its inception and expects to continue to incur significant costs for research and development in the foreseeable future. There is no certainty that the Company will become profitable in the future. The Company will require additional capital to meet its long-term operating requirements. It expects to raise additional capital through, among other things, the sale of equity, debt or convertible securities through public offerings or private placements, including sales of ADSs pursuant to the Current ATM Offering. If adequate funds are not available in the future, The Company’s ability to raise additional capital may be adversely impacted by the potential worsening of global economic and political conditions and volatility in the credit and financial markets in the U.S. and worldwide. This could be exacerbated by, among other factors, the war between Russia and Ukraine, the ongoing conflict in the Middle East or other macroeconomic conditions. The Company’s failure to raise capital as and when needed, or on acceptable terms could have a negative impact on the Company’s financial condition, its ability to continue as a going concern, and its ability to pursue its business strategy, and the Company may have to delay, reduce the scope of, suspend or eliminate one or more of its research-stage programs, clinical trials, or future commercialization efforts. Quantitative and qualitative disclosure about market risk The Company is exposed to market risks in the ordinary course of its business. Market risk represents the risk of loss that may impact the Company’s financial position due to adverse changes in financial market prices and rates. The Company’s current investment policy is conservative due to the need to support operations. The Company invests available cash in Italian and U.S. government treasury bills and notes with short-term maturities. The Company is an early-stage cell and gene therapy company commercializing technology licensed from OSR. The Company intends to continue to conduct its operations so that neither it nor its subsidiary is required to register as an investment company under the Investment Company Act of 1940, as amended, and the rules and regulations promulgated thereunder (the “‘40 Act”). To ensure that the Company does not become subject to regulation under the ‘40 Act, the Company may be limited in the type of assets that it may own or acquire. If the Company were to become inadvertently subject to the ‘40 Act, any violation of the ‘40 Act could subject the Company to material adverse consequences. Foreign currency exchange risk The Company’s results of operations and cash flow may be subject to fluctuations due to changes in foreign currency exchange rates. The Company’s liquid assets and expenses are denominated in EUR and USD. At June 30, 2024, the Company maintained € 6.2 10.7 Currently, the Company has recorded an unrealized net gain from exchange rate of approximately € 0.2

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of significant accounting policies	2. Summary of significant accounting policies Basis of presentation The consolidated financial statements of the Company are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial reporting and in accordance with Regulation S-X, Rule 10-01 promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, the financial statements may not include all the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 20-F filed with the SEC on March 29, 2024, as amended by Amendment No. 1 of Form 20-F/A filed with the SEC on April 1, 2024. The balance sheet as of December 31, 2023 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of the Company’s management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year. A summary of the significant accounting policies applied in the preparation of these consolidated financial statements is presented below, only for the categories and headings now applicable and that might be applicable in the future based on the Company’s business. These policies have been consistently applied, unless otherwise stated. Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts reported in the financial statements and the disclosures made in the accompanying notes. Estimates and assumptions reflected in these consolidated financial statements include but are not limited to, the accrual for research and development and clinical expenses and related milestone payments, share-based compensation expense, valuation of research and development tax credits, the valuation of equity and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are recorded in the period in which they become known. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed below. Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents like short-term marketable securities, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. In the Consolidated Statements of Cash Flows, cash and cash equivalents include cash on hand, deposits held with banks, and other short-term highly liquid investments. In the consolidated balance sheets, bank overdrafts, if any, are shown in current liabilities. Cash and cash equivalents are reported at fair value and are detailed as follows: Schedule of cash and cash equivalents At June 30, At December 31, 2024 2023 (Unaudited) Cash in bank € 3,945,143 € 3,687,402 Cash in short-term marketable securities 2,238,823 - Cash in hand & prepaid cards 4,000 4,018 Total cash and cash equivalents € 6,187,966 € 3,691,420 Marketable securities The Company’s marketable securities are maintained by management and investment managers and consist of highly rated domestic and foreign government debt securities. Debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of shareholders’ equity until realized. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest income, net. Realized gains and losses on debt securities are determined using the specific identification method and are included in other income(expense), net. The Company classifies marketable securities with a remaining maturities Effective January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the Consolidated Statements of Operations and Comprehensive Loss as credit loss expense within other income (expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit loss on its available-for-sale debt securities. Accrued interest receivable related to the Company’s available-for-sale debt securities is presented within receivables and other current assets on the Company’s Consolidated Balance Sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write-offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities. Net loss and comprehensive loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 Comprehensive Income requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the six months ended June 30, 2024, the net loss was equal to € 4.0 4.1 Net loss per share Net loss per share (“EPS”) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period increased by the number of additional ordinary shares that would have been outstanding if all potential ordinary shares had been issued and were dilutive. The EPS calculation was applied at the Company conversion to an 2021. Prior conversion to an S.p.A., Company’s equity interests were represented by quotas, as opposed to and accordingly, an not have 59.7 million ordinary shares. In July 2023, in the Prior ATM Offering, 100 new ADSs were issued. In March 2024, 72,908 additional ADSs were issued in the Current ATM Offering. At June 30, 2024, the Company had 18,289,866 ordinary shares issued and outstanding, with approximately 1.8 million ordinary shares reserved for the Company’s Equity Incentive Plan 2021–2035. At June 30, 2024 and June 30, 2023, the Company had options on 280,033 and 318,459 ordinary shares outstanding, respectively, and 23,502 ordinary share equivalents in the form of underwriters’ ordinary share warrants. Dr. Squinto, the Company’s former Chairman of the Board, 147,783 shares that expired unexercised as of April 2024. Diluted EPS was not relevant at June 30, 2024 and June 30, 2023, as the effect of ordinary share equivalents, in the form of 23,502 280,033 318,459 Foreign currency translation The reporting and functional currency of the Company is Euros. All amounts are presented in Euros unless otherwise stated. All amounts disclosed in the consolidated financial statements and notes have been rounded to the nearest Euro unless otherwise stated. Foreign currency transactions, if any, are translated into Euros using the exchange rates prevailing at the date(s) of the transaction(s) or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the Consolidated Statements of Operations and Comprehensive Loss. For financial reporting purposes, the assets and liabilities of the U.S. Subsidiary are translated into EUR using exchange rates in effect at the balance sheet date. The net income/(loss) of the U.S. Subsidiary is translated into EUR using average exchange rates in effect during the reporting period. The resulting currency translation impact is recorded in the Consolidated Statements of Changes in Shareholders’ Equity as a cumulative translation adjustment. At June 30, 2024 and June 30, 2023, the currency translation impact was not material. During the six months ended June 30, 2024, the unrealized foreign exchange net gain was € 0.2 0.2 Emerging growth company status The Company is an “emerging growth company,” as defined in the U.S. Jumpstart Our Business Startups Act (the “JOBS Act”) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an “emerging growth company.” Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and, because of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an “emerging growth company.” Fair value measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of the Company’s research and development (“R&D”) tax credits, VAT credits, accounts payable, accrued expenses and other current liabilities were evaluated and determined to approximate their fair values due to the short-term nature of these assets and liabilities. Schedule of fair values due to short-term nature of assets and liabilities Total Level 1 Level 2 Level 3 June 30, 2024 Total Level 1 Level 2 Level 3 Cash and cash equivalents € 6,187,966 6,187,966 € - € - Marketable securities 10,718,210 10,718,210 - - Total cash and cash equivalents and marketable securities € 16,906,176 € 16,906,176 € - € - Total Level 1 Level 2 Level 3 December 31, 2023 Total Level 1 Level 2 Level 3 Cash and cash equivalents 3,691,420 3,691,420 Marketable Securities € 15,084,284 15,084,284 € - € - Total cash and cash equivalents and marketable securities € 18,775,704 € 18,775,704 € - € - Segment information Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company’s operations, and manages its business, in one operating segment, which is the research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat cancer. Tax credit on investments in R&D In line with the legislation in force at December 31, 2023, and for the fiscal R&D Starting with the fiscal year 2023 (“FY 2023”), for eligible R&D 5.0 million. In addition, the law extended the measure up to the tax period ended December 31, 2031. The eligible activities consist of fundamental research, industrial research, and experimental development as defined respectively of the letters m), q) and j) of point 15, par. 1.3 of the Communication no. 198/2014 of the European Commission. To determine the cost basis of the benefit, the following expenses are eligible: ● Personnel costs; ● Depreciation charges, costs of the financial or simple lease and other expenses related to movable tangible assets and software used in R&D ● Expenses for extra-euro research contracts concerning the direct execution of eligible R&D ● Expenses for consulting services and equivalent services related to eligible R&D ● Expenses for materials, supplies, and other similar products used in R&D The Company accounts for this receivable in accordance with International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance While these tax credits can be carried forward indefinitely, the Company recognized an amount that reflects management’s best estimate of the amount that is reasonably assured to be realized or utilized in the foreseeable future based on historical benefits realized, adjusted for expected changes, as applicable. The tax credits are recorded as an offset to research and development expenses in the Company’s Consolidated Statements of Operations and Comprehensive Loss. Share-based compensation To reward the efforts of employees, officers, directors, and certain consultants, and to promote the Company’s growth and development, the Board may approve, upon occasion, various share-based awards. The Company’s In June 2023, the Company’s shareholders modified the Plan to extend the final deadline for the issuance of the ordinary shares until December 31, 2035, to allow all stock options granted during the term of the Plan could provide for an exercise period of 10 years Currently, the Company has authorized options on 1,828,986 10 18,289,866 2,700,000 1,828,986 2,700,000 27,000,000 The Company measures its stock option awards granted to employees, officers, directors, and consultants under the Plan based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is normally the vesting period of the respective award. Forfeitures are accounted for as they occur. The measurement date for option awards is the date of the grant. The Company classifies stock-based compensation expense in its Consolidated Statement of Operations and Comprehensive Loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. The Company chose the Black-Scholes-Merton model because it is considered easier to apply and it is a defined equation and incorporates only one set of inputs. As a result, it is the model most commonly in use. Representative warrants Upon the closing of the Company’s IPO, the Company issued 23,502 125 14.375 Non-current assets right-of-use (“ROU”) Upon commencement of a contract containing a lease, the Company classifies leases other than short-term leases as either an operating lease or a finance lease according to the criteria prescribed by ASC 842. The Company recognizes both lease liabilities and ROU assets on the balance sheet for all leases, except for short-term leases (those with a lease term of 12 months or less). Lease liabilities are initially measured at the present value of the future lease payments over the lease term, discounted at the rate implicit in the lease or, if that rate is not readily determinable, the Company’s incremental borrowing rate. The ROU assets represent the lessee’s right to use the underlying asset for the lease term and are initially measured at the same amount as the corresponding lease liability. For finance leases, the Company recognizes interest expense on the lease liability and amortization expense on the ROU asset. For operating leases, lease expense is recognized on a straight-line basis over the lease term. In February 2022, the Company entered into a four-year (i.e., 48-month) lease of an automobile, with an ending date of January 2026. The “base” annual lease payment is € 13,967 1,164 lease payment will remain fixed for the four (4) years For the initial measurement, the calculation of the net present value of the ROU asset and liability was made by using the discounted rate of 6.25 49,320 21,004 13,023 7,981 Fixed Assets Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. Depreciation is systematically recorded in the consolidated financial statements by taking into consideration the use, purpose, and financial-technical duration of the assets, based on their estimated useful economic lives. Leasehold improvement depreciation is recorded based on the shorter of: (i) the life of the leasehold improvement; or, (ii) the remaining term of the lease. Ordinary maintenance costs are expensed to the Consolidated Statements of Operations and Comprehensive Loss in the year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it, and/or to increase its productivity or safety for the purpose of economic productivity of the Company, are attributed to the asset to which they refer and depreciated based on its estimated useful economic life. Amortization of leasehold improvements is computed using the straight-line method based on the terms of the applicable lease or estimated useful life of the improvements, whichever is less. Impairment of long-lived assets In accordance with ASC Topic 360-10-20, ‘‘Property, Plant and Equipment,” the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. To date, no impairments have been identified for the six months ended June 30, 2024, and June 30, 2023. Deferred offering costs Deferred offering costs, which primarily consist of direct, incremental legal and accounting fees relating to fundraising activities (e.g., an IPO or other fundraising activities), are capitalized within prepaid expenses and other current assets before the offering and netted or offset with the offering proceeds upon closing of the offering. For the six months ended June 30, 2024, the Company incurred approximately € 0.2 For the six months ended June 30, 2023, the Company incurred approximately € 0.3 Recently issued accounting pronouncements In November 2023, the FASB issued ASU 2023-07 which amends ASC 280 to improve the information that a public entity discloses about its reportable segments and to address investor requests for more information about reportable segment expenses by requiring incremental disclosures for segment reporting. The effective date for ASU 2023-07 is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The amendment requires companies to disclose more information about their reportable segments, including: (1) (2) (3) (4) (5) In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which modifies the rules on income tax disclosures to require disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. In March 2024, the FASB issued ASU 2024-01, Scope Application of Profits Interest and Similar Awards, which clarifies how an entity determines whether a profits interest or similar award (hereafter a “profits interest award”) is (1) within the scope of Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation, or (2) not a share-based payment arrangement and therefore within the scope of other guidance. For public business entities, ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim periods within those annual periods. The Company currently expects that this ASU will not have a material impact on its consolidated financial statements.

Research and development

Research and development	6 Months Ended
	Jun. 30, 2024
Research and Development [Abstract]
Research and development	3. Research and development Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries, share-based compensation and benefits, facilities costs, third-party license fees, and external costs of outside vendors and consultants engaged to conduct clinical development activities and clinical trials, (e.g., contract research organizations or “CROs”), as well as costs to develop manufacturing processes, perform analytical testing and manufacture clinical trial materials, (e.g., contract manufacturing organizations or “CMOs”). Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition, funding from research grants, if any, is recognized as an offset to research and development expense based on costs incurred on the research program. The Company annually sustains a significant amount of research costs to meet its business objectives. The Company has various research and development contracts, and the related costs are recorded as research and development expenses as incurred. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations at period end to those third parties. Any accrual estimates are based on several factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs. For further details, please refer to the Related Parties disclosures in Note 12. Accumulated Other Comprehensive Income below.

General and administrative

General and administrative	6 Months Ended
	Jun. 30, 2024
General And Administrative
General and administrative	4. General and administrative General and administrative costs consist primarily of salaries, share-based compensation, benefits, and other related costs for personnel and consultants in the Company’s executive and finance functions, professional fees for legal, finance, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include rent and maintenance of facilities and other operating costs not otherwise included in research and development expense.

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income taxes	5. Income taxes The Company is subject to taxation in Italy, and the U.S., through the U.S. Subsidiary. Taxation in Italy includes the standard corporate income tax (“IRES”) and a regional business tax (“IRAP”). Taxation in the U.S. includes federal corporate income tax (“IRS”), as well as state and local taxes. Taxes are recorded on an accrual basis. They therefore represent the allowances for taxes paid or to be paid for the year, calculated according to the current enacted rates and applicable laws. In the future, the Company may be taxed in various other countries where it may have permanent establishments, as applicable. Due to the tax loss position reported, no income taxes were accrued for the six months ending June 30, 2024, and June 30, 2023, in Italy or the U.S. At June 30, 2024, the U.S, subsidiary had an immaterial amount of other state taxes. The Company uses the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities, measured at tax rates expected to be enacted at the time of their reversals. These temporary differences primarily relate to net operating losses carried forward available to offset future taxable income. At each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regard to future realization of deferred tax assets. In consideration of the start-up status of the Company, a valuation allowance has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should the Company conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company’s Consolidated Statements of Operations and Comprehensive Loss. The Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain tax positions that have been recognized in the accompanying consolidated financial statements. For the Company, the prior five years of tax returns (2019-2023) are potentially subject to audit. For the U.S. Subsidiary, the open years for tax examination are 2021, 2022, and 2023. At June 30, 2024, and June 30, 2023, the Company believes there were no significant differences with regard to its deferred tax assets and its relevant components, compared to the computations of the preceding periods. In 2011, the Italian tax authorities issued a set of rules that modified the previous treatment of tax loss carryforwards. According to DL 98/2011, at the end of 2011, all existing tax loss carryforwards will never expire but they can offset only 80 The Company has analyzed its tax position by determining the amount of tax losses that can be carried forward indefinitely and has decided to accrue an allowance for related deferred tax assets as the Company is in a situation of pre-revenues that is destined to remain in the long run and there is no certainty of the future recoverability of such tax losses through tax relevant incomes. Future taxable profits for the Company depend on the manufacture of marketable drugs following the successful completion of the applicable clinical trial. Since the GBM clinical trial is still in Phase 1/2a status, the time frame and uncertainties regarding the outcome of the completion justify the full allowance of deferred tax assets.

Prepaid expenses and other curr

Prepaid expenses and other current assets	6 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses and other current assets	6. Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the following: Schedule of prepaid expenses and other current assets At June 30, At December 31, 2024 2023 (in Euros) (Unaudited) Value added tax (VAT) € 420,366 € 1,170,634 Research and development tax credit 766,680 833,000 Advances payments to suppliers 34,439 34,108 Other current assets 247,946 64,664 Other prepaids 193,866 378,148 Total € 1,663,297 € 2,480,554 Value added tax (“VAT”) receivables are linked to purchases. Italian VAT (Imposta sul Valore Aggiunto) applies to the supply of goods and services carried out in Italy by entrepreneurs, professionals, or artists and on imports carried out by anyone. Intra-Community acquisitions are also subject to VAT under certain situations. The Italian standard VAT rate for 2024 and 2023 is 22 1.7 1.3 0.4 Tax credits on research and development represent a special tax relief offered to Italian companies operating in the research and development sector and can be used to offset most taxes payable. The Company has a total research and development tax credit available to be used of approximately € 4.0 During the six months ended June 30, 2024 and 2023, the Company utilized approximately € 0.4 0.4 The advance payments to suppliers mainly refer to an advance payment to a supplier whose activities are still ongoing based on a service agreement that provides for a discount on this advance payment on the last invoice that will be issued at the end of the works. As of June 30, 2024, other current assets were 0.2 million and financial claims for accrued interest on ongoing investments, amounting to approximately € 53,000 . The change compared to the previous period balance was 180,000 of tax credit related to Italian Additional Corporate Tax (the “ACE tax”) which, based on the latest updates received from the Italian Revenue Agency, will be recovered in the short term. The prepaids refer to accrual adjustments for services that have already been fully invoiced and paid, but whose economic usefulness is distributed over multiple periods beyond the current closing period. These costs mainly concern IT services, licenses, insurance, and manufacturing activities. The change in the prepaid balance is primarily influenced by the trend in manufacturing activities performed by the Company’s manufacturing vendor, AGC Biologics, 0.2 million at June 30, 2023 to approximately € 0.1 million at June 30, 2024.

Fixed assets, net

Fixed assets, net	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Fixed assets, net	7. Fixed assets, net Fixed assets consist of the following: Schedule of fixed assets,net At June 30, At December 31, 2024 2023 (Unaudited) Software (ERP Implementation) € 87,800 € 87,800 Computers 37,840 35,971 Furniture and fixtures 13,005 13,005 Total fixed assets 138,645 136,776 Less: accumulated depreciation (75,931 ) (53,799 ) Fixed assets, net € 62,714 € 82,977 For the period ended June 30, 2024 and June 30, 2023, software was € 87,800 Equipment consists of computers, and furniture and fixtures of our office space in Milan, Italy. There were no significant purchases, disposals or impairments during the periods. Depreciation has been calculated by taking into consideration the use, purpose, and financial-technical duration of the assets, based on their estimated economic lives. No significant purchases occurred during the six months ended June 30, 2024.

Other non-current assets

Other non-current assets	6 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other non-current assets	8. Other non-current assets Other non-current assets consist of the following: Schedule of other non-current assets At June 30, At December 31, 2024 2023 (Unaudited) Value added tax (VAT) 110,774 € 630,342 Research and development tax credit 249,892 167,000 Other non-current assets 21,004 207,218 Total € 381,670 € 1,004,560 The balance of long-term VAT credit is what remains outstanding after the refund of € 0.4 The R&D tax credit long-term portion at June 30, 2024 was approximately € 250,000 167,000 Other non-current assets include the ROU asset for the car lease in the amount of € 21,004 180,000

Retirement benefit obligation

Retirement benefit obligation	6 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Retirement benefit obligation	9. Retirement benefit obligation Employees in Italy are entitled to Trattamento di Fine Rapporto (“TFR”), commonly referred to as an employee leaving indemnity, which represents deferred compensation for employees in the private sector. Under Italian law, an entity is obligated to accrue for TFR on an individual employee basis payable to each individual upon termination of employment (including both voluntary and involuntary dismissal). The annual accrual is approximately 7 The amount of the obligation at June 30, 2024 and December 31, 2023 was € 196,368 164,655

Shareholders_ equity

Shareholders’ equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Shareholders’ equity	10. Shareholders’ equity The number of the Company’s outstanding ordinary shares at December 31, 2022, was 18,216,858 For the six-month period ended June 30, 2023, the Company accrued € 415,433 In July 2023, 100 531 For the six-month period from July 1, 2023 to December 31, 2023, the Company accrued € 324,451 At December 31, 2023, the Company had 18,216,958 1.8 In March 2024, 72,908 new ADSs Prior 270,885 . For the six-months ended June 30, 2024, the Company accrued € 232,768 At June 30, 2024, the Company had 18,289,866 1.8

Share-based compensation

Share-based compensation	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-based compensation	11. Share-based compensation As mentioned in Note 2. Summary of significant accounting policies, to reward the efforts of employees, officers, directors, and certain consultants, and to promote the Company’s growth and development, the Board may approve, upon occasion, various share-based awards. The Plan was originally approved on May 20, 2021 and was subsequently modified, in June 2023, to extend the final deadline for the issuance of the ordinary shares until December 31, 2035, to allow that all stock options granted during the term of the Plan could provide for an exercise period of 10 years starting from the date of grant. At January 1, 2023, there were 540,523 1,281,162 In March 2023, the Board, as administrator of the Plan, awarded non-qualified stock options (“NSOs”) on 46,400 5.62 At December 31, 2023, there were 586,923 1,234,772 In April 2024, NSOs on 147,783 At June 30, 2024, there were 439,140 stock options granted and 1,389,846 options available for grant. The Company calculates the fair value of stock option awards granted to employees and non-employees using the Black-Scholes option-pricing method. If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility and longer expected lives would result in an increase to share-based compensation expense to non-employees determined at the date of grant. Share-based compensation expense to non-employees affects the Company’s general and administrative expenses and research and development expenses. The Company calculated the share compensation expense for the options granted by utilizing the Black-Scholes method with the following inputs for each of the stock grants: ● The option’s exercise price. ● The option’s expected term. ● The underlying share’s current price. ● The underlying share’s expected price volatility during the option’s expected (or in certain cases, contractual) term, or in cases where calculated value is used, the historical volatility of an appropriate industry sector index. ● The underlying share’s expected dividends during the option’s expected (or in certain cases, contractual) term except cases, such as when dividend protection is provided; and, ● The risk-free interest rate during the option’s expected (or in certain cases, contractual) term. Schedule of Outstanding Stock Options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of January 1, 2023 540,523 € 4.99 7.3 € 272,480 Granted 46,400 5.30 9.17 - Vested and exercised - - - - Cancelled or forfeited - - - - Outstanding as of December 31, 2023 586,923 € 4.84 6.53 € 67,596 Exercisable as of December 31, 2023 382,785 € 5.11 5.44 € 33,796 Outstanding, expected to vest as of December 31, 2023 204,138 € 4.34 8.58 € 33,800 Outstanding as of January 1, 2024 586,923 € 4.84 6.53 € 67,596 Granted - - - - Vested and exercised - - - - Cancelled or forfeited (147,783 ) - - - Outstanding as of June 30, 2024 439,140 € 4.53 8.12 € - Exercisable as of June 30, 2024 280,033 € 4.58 8.16 € - Outstanding, expected to vest as of June 30, 2024 159,107 € 4.44 8.05 € - The Company’s share-based compensation expense for the period ended June 30, 2024 and June 30, 2023 is represented by the following table: Schedule of share based compensation expenses 2024 2023 Six Months Ended June 30, 2024 2023 Research & development expense € 37,173 € 36,718 Research & development expense - related party - - General & administrative expense 114,219 298,333 General & administrative expense- related party 81,376 80,381 Total € 232,768 € 415,433 Unrecognized expense € 747,043 € 1,471,743 For the six months ended June 30, 2024, and June 30, 2023, the Company recorded € 232,768 415,433 747,043 1,471,743 There were no 5.30 Weighted average shares The calculation was performed by taking the number of shares outstanding during a given period and weighting them for the number of days that number of shares were outstanding. For the six months ended June 30, 2024, and June 30, 2023, there was a weighted average of 18,256,622 18,216,858 no

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Accumulated Other Comprehensive Income	12. Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income Unrealized gains and losses on available-for-sale debt securities Foreign Currency Translation Adjustments Total Changes in Accumulated Other Comprehensive Income For the Period Ending June 30, 2024 Unrealized gains and losses on available-for-sale debt securities Foreign Currency Translation Adjustments Total Beginning Balance € 214,984 € 16,158 € 231,142 Adjustment for net gain on marketable securities (190,228 ) (190,228 ) Change in fair value of marketable securities 125,940 125,940 Cumulative translation adjustment - (16,081 ) (16,081 ) Total € 150,696 € 77 € 150,773 Accumulated Other Comprehensive Income relates to marketable securities fair value measurement reserve and cumulative translation adjustment reserve as reported in the above table. The net realized gain in the six months ended June 30, 2024 from the Company’s investing activity was approximately € 0.2 0.1 The cumulative translation adjustments reserve was not material, and it mainly included the effect of the translation of U.S. dollars held by the

Related parties

Related parties	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related parties	13. Related parties The Company’s R&D Schedule of third party and related party expenses Six Months Ended June 30, 2024 Third Parties Related Parties Total Consultants & other third parties € 113,498 € 303,298 € 416,796 Materials & supplies 911,246 - 911,246 Compensation (including share-based) 349,839 329,227 679,066 Travel & entertainment 17,589 - 17,589 Other 15,693 - 15,693 Total € 1,407,865 € 632,525 € 2,040,390 Six Months Ended June 30, 2023 Third Parties Related Parties Total (Unaudited) Consultants & other third parties € 150,402 € 72,500 € 222,902 Materials & supplies 2,464,107 660,863 3,124,970 Compensation (including share-based) 212,003 330,796 542,799 Travel & entertainment 27,892 - 27,892 Other 3,239 - 3,239 Total € 2,857,643 € 1,064,159 € 3,921,802 Related party R&D R&D R&D The Company’s general and administrative expenses are also a combination of third-party and related-party expenses, as detailed below: Schedule of third party and general and administrative expenses Six Months Ended June 30, 2024 Third Parties Related Parties Total Compensation (including share-based) € 451,903 € 698,620 € 1,150,523 Accounting, legal & other professional 557,049 - 557,049 Communication & IT related facility 85,277 85,277 Facility & insurance related 984 8,120 9,104 Consultants & other third parties 324,306 - 324,306 Other 350,752 967 351,719 Total € 1,770,271 € 707,707 € 2,477,978 Six Months Ended June 30, 2023 Third Parties Related Parties Total (Unaudited) Compensation (including share-based) € 697,228 € 673,795 € 1,371,023 Accounting, legal & other professional 720,989 - 720,989 Communication & IT related facility - - - Facility & insurance related 2,868 8,171 11,039 Consultants & other third parties 314,059 - 314,059 Other 460,320 943 461,263 Total € 2,195,464 € 682,909 € 2,878,373 The Company’s accounts payable to related parties are comprised as follows: Schedule of accounts payable to related parties At June 30, At December 31, 2024 2023 (Unaudited) San Raffaele Hospital € 189,762 € 170,888 The Company’s accrued expenses to related parties are comprised as follows: Schedule of accrued expenses to related parties At June 30, At December 31, 2024 2023 (Unaudited) San Raffaele Hospital € 34,306 € 413,935 Pierluigi Paracchi 252,000 175,254 Richard Slansky 176,812 116,738 Carlo Russo 235,750 155,651 Total € 698,868 € 861,578 The Company has identified the following related parties: ● Pierluigi Paracchi ● Luigi Naldini ● Bernard Rudolph Gentner ● Carlo Russo ● Richard Slansky and, ● Ospedale San Raffaele These parties could exercise significant influence on the Company’s strategic decisions, behavior, and future plans. The following is a description of the nature of the transactions between the Company and these related parties: Pierluigi Paracchi Mr. Pierluigi Paracchi, is the Company’s Chief Executive Officer, Chairman, as well as co-founder. His current employment arrangement with the Company provides an annual gross salary of € 420,000 plus a 40 % annual bonus subject to Board approval. Mr. Paracchi also has use of a Company car, for which the Company entered an operating lease agreement that In March 2023, Mr. Paracchi was paid a bonus of approximately € 112,000 At December 31, 2023, the Company accrued € 168,000 84,000 84,000 For the six months ended June 30, 2024 and June 30, 2023, the Company expensed approximately € 300,000 Luigi Naldini/Bernard Rudolph Gentner Drs. Luigi Naldini and Bernhard Gentner are co-founders of Genenta and part of the Scientific Advisory Board (“SAB”), with Dr. Naldini as Chairman, and Dr. Gentner as a member. The Company has consulting agreements with each of Drs. Naldini and Gentner. Dr. Naldini has an advisory agreement approved by the Board and he and his staff perform the pre-clinical studies for the Company. The latest consulting agreement with Dr. Naldini was signed on June 20, 2022, which includes an annual fee of € 100,000 50,000 Dr. Gentner, like Dr. Naldini, oversees pre-clinical research related to the Company’s platform technology and analyzes clinical biological data. The consulting agreement with Dr. Gentner started on July 1, 2022, and provides fees in the amount of € 45,000 22,500 In February 2024, Dr. Gentner entered into an addendum to the consulting agreement in which the Company agrees to pay a total one-time fee of up to € 15,000 5,000 Carlo Russo Dr. Carlo Russo serves the Company as Chief Medical Officer and Head of Development and is responsible for the clinical development of Temferon™, the Company’s gene therapy platform. His current employment arrangement is in place with the U.S. Subsidiary, and it provides for an annual gross salary of $ 500,000 30 In March 2023, Dr. Russo was paid a bonus of approximately € 112,000 At December 31, 2023, the Company accrued € 156,000 84,000 70,000 For the six months ended June 30, 2024, and June 30, 2023, the Company expensed approximately € 329,000 331,000 Richard Slansky Mr. Richard Slansky is the Chief Financial Officer of the Company. His current employment arrangement is in place with the U.S. Subsidiary, and it provides an annual gross compensation of $ 375,000 30 At December 31, 2023 the Company accrued € 116,000 63,000 53,000 For the six months ended June 30, 2024, and June 30, 2023, the Company expensed approximately € 243,000 253,000 OSR – San Raffaele Hospital OSR - San Raffaele Hospital is a co-founder of the Company, and the Company is a corporate and research spin-off of OSR. OSR is one of the leading biomedical research institutions in Italy and Europe, with a 45-year history of developing innovative therapies and procedures. The Company has agreements to license technology, to perform research, pre-clinical and clinical activities, as well as to lease facilities, and obtain certain other support functions. The Company’s headquarters is currently located in an OSR facility. Amended and Restated OSR License Agreement The Company entered into an amended and restated license agreement (the “ARLA”) with OSR in March 2023. The ARLA replaced the Company’s original license agreement originally entered into with OSR on December 15, 2014, as subsequently amended on March 16, 2017, February 1, 2019, December 23, 2020, September 28, 2021, January 22, 2022, September 29, 2022, and December 22, 2022 (the “Original OSR License Agreement”). The effectiveness of the ARLA was subject to Italy’s Law Decree No. 21 of March 15, 2012 (i.e., the Italian Golden Power regulations), as subsequently amended and supplemented and would not become effective until the applicable Italian governmental authority consented to the ARLA. On April 20, 2023, such consent was received, and the ARLA became effective. Pursuant to the terms of the ARLA, OSR has granted the Company an exclusive, royalty-bearing, non-transferrable (except with the prior written consent of OSR), sublicensable, worldwide license, subject to certain retained rights, to (1) certain patents, patent applications and existing know-how for the use in the field(s) of Interferon (“IFN”) gene therapy by lentiviral based-hematopoietic stem and progenitor cells (“HSPC”) gene transfer with respect to any solid cancer indication (including glioblastoma and solid liver cancer) and/or any lympho-hematopoietic indication for which the Company exercises an option (described below); and, (2) certain gene therapy products (subject to certain specified exceptions related to replication competent viruses) developed during the license term for use in the aforementioned field(s) consisting of any lentivirals or other viral vectors regulated by miR126 and/or miR130 and/or other miRs with the same expression pattern as miR126 and miR130 in hematopoietic cells for the expression of IFN under the control of a Tie2 promoter. Lympho-hematopoietic indication means any indication related to lympho-hematopoietic malignancies and solid cancer indication means any solid cancer indication (e.g., without limitation, breast, pancreas, colon cancer), with each affected human organ counting as a specific solid cancer indication. The rights retained by OSR, and extending to its affiliates, include the right to use the licensed technology for internal research within the field(s) of use, the right to use the licensed technology within the field(s) of use other than in relation to the licensed products, and the right to use the licensed technology for any use outside the field(s) of use, but subject to the options described below. In addition, the Company granted OSR a perpetual, worldwide, royalty-free, non-exclusive license to any improvement generated by the Company with respect to the licensed technology, to conduct internal research within the field(s) of use directly, or in or with the collaboration third parties; and, for any use outside the field(s) of use, in which case the license is sublicensable by OSR. Finally, the worldwide rights for the field(s) of use granted to the Company regarding the Lentigen know-how are non-exclusive and cannot be sublicensed due to a pre-existing nonexclusive sublicense to these rights between OSR and GlaxoSmithKline Intellectual Property Development Limited. Pursuant to the ARLA, the Company has an exclusive option exercisable until April 20, 2026 to any OSR product improvements at no additional cost, which could be useful for the development and/or commercialization of licensed products in the field of use. The Company also has an exclusive option exercisable until April 20, 2026 (the “LHI Option Period”) to any lympho-hematopoietic indication(s) to be included as part of the field of use, on an indication-by-indication basis, subject to the payment of specified option fees and milestone payments: ● € 1.0 ● € 0.5 ● € 0.3 No option fee is due for the fourth lympho-hematopoietic indication and any subsequent lympho-hematopoietic indications. The Company has the right to extend the LHI Option Period twice for additional 12-month periods, subject to the payment of specified extension fees. Prior to the effective date of the ARLA, the Company paid OSR an upfront fee in an amount equal to € 250,000 Pursuant to the ARLA, as consideration, the Company agreed to pay OSR additional license fees equal to up to € 875,000 As part of the ARLA, the Company has agreed to use reasonable efforts to involve OSR in Phase I clinical trials for licensed products in the field of use, subject to OSR maintaining any required quality standards and providing its services on customary and reasonable terms and consistent with then-applicable market standards. The Company is also obligated to carry out its development activities using qualified and experienced professionals and sufficient level of resources. In particular, consistent with the terms of the Original OSR License Agreement, the ARLA continues to require the Company to invest (a) at least €5,425,000 with respect to the development of the licensed products, and (b) at least €2,420,000 with respect to the manufacturing of such licensed products (subject to certain adjustments). OSR maintains control of the preparation, prosecution, and maintenance of the patents licensed. The Company is obligated to pay those costs unless additional licensees benefit from these rights, in which case the cost will be shared pro rata The ARLA expires upon the expiry of the “Royalty Term” for all licensed products and all countries, unless terminated earlier. The Royalty Term begins on the first commercial sale of a licensed product in each country, on a country by country basis, and ends upon the later of the (a) expiration of the commercial exclusivity for such product in that country (wherein the commercial exclusivity refers to any remaining valid licensed patent claims covering such licensed product, any remaining regulatory exclusivity to market and sell such licensed product or any remaining regulatory data exclusivity for such licensed product), and (b) 10 years from the first commercial sale of such licensed product in such country. The parties may terminate the agreement in the event the other party breaches its obligations therein, which termination shall become effective 60 business days following written notice thereof to the breaching party. The breaching party shall have the right to cure such breach or default during such 60 business days. OSR may terminate the agreement for failure to pay in the event that the Company fails to pay any of the upfront payments, additional license fees, sublicensing income or milestone payments within 30 days of due dates for each. In addition, OSR may terminate (with a 60-business day prior written notice) the Company’s rights as to certain fields of use for the Company’s failure to achieve certain development milestones for specified licensed products within certain time periods, which may be subject to extension. In addition, OSR may terminate the agreement in the event that commercialization of a licensed product is not started within 24 months from the grant of both (i) the MAA approval and (ii) the pricing approval of such licensed product, provided that such termination will relate solely to such licensed product and to such country or region to which both such MAA approval and pricing approval were granted. Amendment to OSR Amended and Restated License Agreement On September 28, 2023, the Company and OSR entered into an amendment to the ARLA, whereby the Company and OSR agreed that the Company had fulfilled the obligations as set forth in the ARLA specific to Candidate Products 1 pursuant to the CP1 SRA (each as defined below). At June 30, 2024, the cumulative total amount of expenses for the OSR clinical trial activity from inception amounted to approximately € 11.0 1.0 0.4 At June 30, 2024, there were no pending activities with OSR related to any agreement in place prior to the ARLA effective date, except for the project called “TEM-MM unspent budget reallocated to the TEM-GBM study”, for which the last tranche of activities corresponding to the 20% of the total project approximately amounting to € 0.2 OSR Sponsor Research Agreement On August 1, 2023, the Company entered into a Sponsored Research Agreement (“CP1 SRA”), which was contemplated under the ARLA, pursuant to which the Company will fund feasibility studies for certain gene therapy products consisting of any lentiviral vectors regulated by miR126 and/or miR130 and/or other miRs with the same expression pattern as miR126 and miR130 in hematopoietic cells for the expression of IFN under the control of a Tie2 promoter, in combination with any immunotherapy (“Candidate Products 1”), along with three additional research projects, to be conducted at OSR. If OSR determines that additional funds are needed, OSR will inform the Company and provide an estimate for completing the research. During the period from the date of execution from the CP1 SRA until six months from the last report delivered to the Company under the CP1 SRA (the “CP1 Option Period”), the Company has the exclusive option to include certain intellectual property related to Candidate Products 1 and Candidate Products 1 as part of the licensed patents and licensed products under the ARLA. To exercise this option, the Company must pay an option exercise fee. The Company also has the right to extend the CP1 Option Period twice for an additional 24-month period. The extension requires payment of an extension fee for each 24-month extension. At June 30, 2024 the Company recorded and paid approximately € 0.3 Operating leases The Company entered into a non-cancelable lease agreement for office space in January 2020. (See Note 14.

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	14. Commitments and contingencies The Company exercises considerable judgment in determining the exposure to risks and recognizing provisions or providing disclosure for contingent liabilities related to pending litigations or other outstanding claims and liabilities. Judgment is necessary in assessing the likelihood that a pending claim will succeed, or a liability will arise and to quantify the possible range of the final settlement. Provisions are recorded for liabilities when losses are considered probable and can be reasonably estimated. Because of the inherent uncertainties in making such judgments, actual losses may be different from the originally estimated provision. Estimates are subject to change as new information becomes available, primarily with the support of internal specialists or outside consultants, such as actuaries or legal counsel. Adjustments to provisions may significantly affect future operating results. The following table summarizes the Company’s obligations by contractual maturity on June 30, 2024: Schedule of company obligations by contractual maturity Payments by Period Total Less than a year 1 to 3 years 4 to 5 years More than 5 years OSR operating leases and office rent € 21,267 € 15,012 € 6,255 € - € - OSR- ARLA 166,700 166,700 - - - AGC manufacturing 75,985 75,985 - - - Insurance policies 11,095 6,996 4,099 - - Total € 275,047 € 264,693 € 10,354 € - € - The commitments with OSR relate to the office rent agreement and the ARLA while the commitments with AGC Biologics (“AGC”) relate to product manufacturing and biologic stability studies on plasmid batches. Insurance on operating leases arise related to the non-lease insurance component of the Company’s auto lease agreement, which was entered into in February 2022 and has a term of four (4) years. The Company has not included future milestones and royalty payments in the table above because the payment obligations under these agreements are contingent upon future events, such as the Company’s achievement of specified milestones or generating product sales, and the amount, timing, and likelihood of such payments are unknown and are not yet considered probable. CMO and CRO agreements The Company enters into contracts in the normal course of business with CMOs, CROs, and other third parties for exploratory studies, manufacturing, clinical trials, testing, and services (shipments, travel logistics, etc.). These contracts do not contain minimum purchase commitments and, except as discussed below, are cancelable by the Company upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of the Company’s vendors or third-party service providers, up to the date of cancellation. These payments are not included in the table above as the amount and timing of such payments are not known. OSR - San Raffaele Hospital As part of the ARLA, the Company is obligated to carry out development activities using qualified and experienced professionals and a sufficient level of resources. In particular, consistent with the terms of the Original OSR License Agreement, the ARLA continues to require the Company to invest (a) at least € 5,425,000 The Company incurred € 0.9 1.6 10.1 The Company has agreed to pay OSR royalties for 4 No events have occurred or have been achieved (and none are considered probable) to trigger any contingent payments under the ARLA during the six months ended June 30, 2024. AGC Biologics S.p.A. The AGC agreement dated March 6, 2019 (the “Master Service Agreement”) is non-cancelable, except in the case of breach of contract, and includes a potential milestone of € 0.3 0.5 1.0 0.5 1.0 In October 2022, the Company entered into Side Letter to the Master Service Agreement dated March 6, 2019 to negotiate a technology transfer agreement regarding the transfer and implementation of the manufacturing process in the AGC facility located in Bresso, Italy, including timeline, budget and the technology transfer protocol (the “Tech Transfer”) and AGC agreed with the Company to procure raw materials to be used under the Tech Transfer. In December 2022, the Company signed respectively: (i) the Amendment No. 1 to the Master Service Agreement mainly to update the definition of raw materials; and (ii) a Process Transfer Agreement to agree on producing the raw materials necessary for the performance of the services related to the Tech Transfer for a total commitment of € 405,000 40,500 24,000 In January 2023, the Company entered into a new Development and Manufacturing Service Agreement providing the framework under which AGC will provide services pursuant to one or more work statements to be entered into from time to time during the agreement term. In February 2023, the Company entered into work statements Nos. 1 and 2 to produce Lentiviral Vector (“LVV”) for ex-vivo application (TIA-126-LV) for an estimated amount, including raw material and third-party costs, of approximately € 0.7 1.5 0.2 In December 2023, the Company entered into purchase orders Nos. 41 and 42 under the Master Service Agreement, for a total amount of approximately € 0.2 In January 2024, the Company entered into a new project change order No. 1 “For the Process Transfer Agreement,” 8,000 . During the six months ended June 30, 2024, the Company entered into purchase orders Nos. 43, 44 and 45 under the Master Service Agreement, for a total amount of approximately € 0.3 million. At June 30, 2024, the production activity was not completed for purchase order No. 43 and not begun for purchase orders Nos. 44 and 45, and was below In June 2024, the Company entered into a work order for the development studies on frozen apheresis and liquid cultures implementation for an estimated amount including raw materials of approximately € 0.3 Operating lease - office rent On January 1, 2020, the Company began a six-year non-cancelable lease agreement for office space with OSR. Withdrawal is allowed from the fourth year with a notice of 12 months. Since the annual rent amounts approximately € 15,150 7,575 Finance lease On February 11, 2022, the Company entered a four (4) year auto lease. This lease has been recognized as a finance lease. The automobile underlying the lease agreement is fully covered by insurance policies for the duration of the lease agreement, for a total amount of € 27,985 11,000 Legal proceedings The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of ASC 450, Contingencies.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent events	15. Subsequent events AGC Biologics S.p.A. In July 2024: - the Company signed a purchase order with AGC, named ‘Bresso Preparatory Activities’, specifically for a one-time fee applicable to all ongoing activity programs and intended for the performance of the same manufacturing activities for € 0.1 - the Company signed a purchase order with AGC, No.46, for a total amount of approximately € 0.1 - the Company cancelled purchase orders with AGC, Nos. 44 and 45, and, as a consequence, the Company will incur a cancellation fee of approximately € 112,000 - on September 19, 2024, an Amendment to the Master Service Agreement was signed with AGC. The purpose of the amendment was to extend the term of the Master Service Agreement to June 30, 2025. The amendment was considered effective retroactive from March 5, 2024, the day on which the Master Service Agreement expired, to cover the preceding period during which the same MSA continued to be operating. In September 2024: - the Company signed two purchase orders with AGC, GU_01 and GU_02, for approximately € 159,000 In October 2024: - the Company signed a purchase order with AGC, No.47, for a total amount of approximately € 0.1 Share-based compensation In July 2024, the Board, as the administrator of the Equity Incentive Plan 2021-2025, awarded NSOs on 577,884 10 10 three years 3.083 Status of proposed Renal Cell Cancer trials In October 2024, the Company announced that the Agenzia Italiana del Farmaco approved a new Phase 1 clinical trial for metastatic Renal Cell Cancer. The Company expects to commence the trial in the fourth quarter of 2024. In October 2024, the Company also entered into an agreement with OSR to conduct an open-label phase 1/2 clinical trial in Renal Cell Cancer. The study is designed to evaluate the safety, biological response, and efficacy of a single dose of Temferon (autologous hematopoietic stem and progenitor cells enriched with CD34+ and genetically modified with human Interferon-α2) in patients with metastatic renal carcinoma.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The consolidated financial statements of the Company are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial reporting and in accordance with Regulation S-X, Rule 10-01 promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, the financial statements may not include all the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 20-F filed with the SEC on March 29, 2024, as amended by Amendment No. 1 of Form 20-F/A filed with the SEC on April 1, 2024. The balance sheet as of December 31, 2023 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of the Company’s management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year. A summary of the significant accounting policies applied in the preparation of these consolidated financial statements is presented below, only for the categories and headings now applicable and that might be applicable in the future based on the Company’s business. These policies have been consistently applied, unless otherwise stated.
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts reported in the financial statements and the disclosures made in the accompanying notes. Estimates and assumptions reflected in these consolidated financial statements include but are not limited to, the accrual for research and development and clinical expenses and related milestone payments, share-based compensation expense, valuation of research and development tax credits, the valuation of equity and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are recorded in the period in which they become known. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed below.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents like short-term marketable securities, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. In the Consolidated Statements of Cash Flows, cash and cash equivalents include cash on hand, deposits held with banks, and other short-term highly liquid investments. In the consolidated balance sheets, bank overdrafts, if any, are shown in current liabilities. Cash and cash equivalents are reported at fair value and are detailed as follows: Schedule of cash and cash equivalents At June 30, At December 31, 2024 2023 (Unaudited) Cash in bank € 3,945,143 € 3,687,402 Cash in short-term marketable securities 2,238,823 - Cash in hand & prepaid cards 4,000 4,018 Total cash and cash equivalents € 6,187,966 € 3,691,420
Marketable securities	Marketable securities The Company’s marketable securities are maintained by management and investment managers and consist of highly rated domestic and foreign government debt securities. Debt securities are carried at fair value with the unrealized gains and losses included in other comprehensive income (loss) as a component of shareholders’ equity until realized. Any premium arising at purchase is amortized to the earliest call date and any discount arising at purchase is accreted to maturity. Amortization and accretion of premiums and discounts are recorded in interest income, net. Realized gains and losses on debt securities are determined using the specific identification method and are included in other income(expense), net. The Company classifies marketable securities with a remaining maturities Effective January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326 as of each reporting date to determine if a portion of any decline in fair value below carrying value recognized on its available-for-sale debt securities is the result of a credit loss. The Company records credit losses in the Consolidated Statements of Operations and Comprehensive Loss as credit loss expense within other income (expense), net, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit loss on its available-for-sale debt securities. Accrued interest receivable related to the Company’s available-for-sale debt securities is presented within receivables and other current assets on the Company’s Consolidated Balance Sheets. The Company has elected to exclude accrued interest receivable from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest receivable once it has determined that the asset is not realizable. Any write-offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not written off any accrued interest receivables associated with its marketable securities.
Net loss and comprehensive loss	Net loss and comprehensive loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 Comprehensive Income requires that an entity records all components of comprehensive (loss) income, net of their related tax effects, in its financial statements in the period in which they are recognized. For the six months ended June 30, 2024, the net loss was equal to € 4.0 4.1
Net loss per share	Net loss per share Net loss per share (“EPS”) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period increased by the number of additional ordinary shares that would have been outstanding if all potential ordinary shares had been issued and were dilutive. The EPS calculation was applied at the Company conversion to an 2021. Prior conversion to an S.p.A., Company’s equity interests were represented by quotas, as opposed to and accordingly, an not have 59.7 million ordinary shares. In July 2023, in the Prior ATM Offering, 100 new ADSs were issued. In March 2024, 72,908 additional ADSs were issued in the Current ATM Offering. At June 30, 2024, the Company had 18,289,866 ordinary shares issued and outstanding, with approximately 1.8 million ordinary shares reserved for the Company’s Equity Incentive Plan 2021–2035. At June 30, 2024 and June 30, 2023, the Company had options on 280,033 and 318,459 ordinary shares outstanding, respectively, and 23,502 ordinary share equivalents in the form of underwriters’ ordinary share warrants. Dr. Squinto, the Company’s former Chairman of the Board, 147,783 shares that expired unexercised as of April 2024. Diluted EPS was not relevant at June 30, 2024 and June 30, 2023, as the effect of ordinary share equivalents, in the form of 23,502 280,033 318,459
Foreign currency translation	Foreign currency translation The reporting and functional currency of the Company is Euros. All amounts are presented in Euros unless otherwise stated. All amounts disclosed in the consolidated financial statements and notes have been rounded to the nearest Euro unless otherwise stated. Foreign currency transactions, if any, are translated into Euros using the exchange rates prevailing at the date(s) of the transaction(s) or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the Consolidated Statements of Operations and Comprehensive Loss. For financial reporting purposes, the assets and liabilities of the U.S. Subsidiary are translated into EUR using exchange rates in effect at the balance sheet date. The net income/(loss) of the U.S. Subsidiary is translated into EUR using average exchange rates in effect during the reporting period. The resulting currency translation impact is recorded in the Consolidated Statements of Changes in Shareholders’ Equity as a cumulative translation adjustment. At June 30, 2024 and June 30, 2023, the currency translation impact was not material. During the six months ended June 30, 2024, the unrealized foreign exchange net gain was € 0.2 0.2
Emerging growth company status	Emerging growth company status The Company is an “emerging growth company,” as defined in the U.S. Jumpstart Our Business Startups Act (the “JOBS Act”) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an “emerging growth company.” Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and, because of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its IPO or such earlier time that it is no longer an “emerging growth company.”
Fair value measurements	Fair value measurements Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. ● Level 3 — Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The carrying values of the Company’s research and development (“R&D”) tax credits, VAT credits, accounts payable, accrued expenses and other current liabilities were evaluated and determined to approximate their fair values due to the short-term nature of these assets and liabilities. Schedule of fair values due to short-term nature of assets and liabilities Total Level 1 Level 2 Level 3 June 30, 2024 Total Level 1 Level 2 Level 3 Cash and cash equivalents € 6,187,966 6,187,966 € - € - Marketable securities 10,718,210 10,718,210 - - Total cash and cash equivalents and marketable securities € 16,906,176 € 16,906,176 € - € - Total Level 1 Level 2 Level 3 December 31, 2023 Total Level 1 Level 2 Level 3 Cash and cash equivalents 3,691,420 3,691,420 Marketable Securities € 15,084,284 15,084,284 € - € - Total cash and cash equivalents and marketable securities € 18,775,704 € 18,775,704 € - € -
Segment information	Segment information Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company’s operations, and manages its business, in one operating segment, which is the research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat cancer.
Tax credit on investments in R&D	Tax credit on investments in R&D In line with the legislation in force at December 31, 2023, and for the fiscal R&D Starting with the fiscal year 2023 (“FY 2023”), for eligible R&D 5.0 million. In addition, the law extended the measure up to the tax period ended December 31, 2031. The eligible activities consist of fundamental research, industrial research, and experimental development as defined respectively of the letters m), q) and j) of point 15, par. 1.3 of the Communication no. 198/2014 of the European Commission. To determine the cost basis of the benefit, the following expenses are eligible: ● Personnel costs; ● Depreciation charges, costs of the financial or simple lease and other expenses related to movable tangible assets and software used in R&D ● Expenses for extra-euro research contracts concerning the direct execution of eligible R&D ● Expenses for consulting services and equivalent services related to eligible R&D ● Expenses for materials, supplies, and other similar products used in R&D The Company accounts for this receivable in accordance with International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance While these tax credits can be carried forward indefinitely, the Company recognized an amount that reflects management’s best estimate of the amount that is reasonably assured to be realized or utilized in the foreseeable future based on historical benefits realized, adjusted for expected changes, as applicable. The tax credits are recorded as an offset to research and development expenses in the Company’s Consolidated Statements of Operations and Comprehensive Loss.
Share-based compensation	Share-based compensation To reward the efforts of employees, officers, directors, and certain consultants, and to promote the Company’s growth and development, the Board may approve, upon occasion, various share-based awards. The Company’s In June 2023, the Company’s shareholders modified the Plan to extend the final deadline for the issuance of the ordinary shares until December 31, 2035, to allow all stock options granted during the term of the Plan could provide for an exercise period of 10 years Currently, the Company has authorized options on 1,828,986 10 18,289,866 2,700,000 1,828,986 2,700,000 27,000,000 The Company measures its stock option awards granted to employees, officers, directors, and consultants under the Plan based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is normally the vesting period of the respective award. Forfeitures are accounted for as they occur. The measurement date for option awards is the date of the grant. The Company classifies stock-based compensation expense in its Consolidated Statement of Operations and Comprehensive Loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. The Company chose the Black-Scholes-Merton model because it is considered easier to apply and it is a defined equation and incorporates only one set of inputs. As a result, it is the model most commonly in use.
Representative warrants	Representative warrants Upon the closing of the Company’s IPO, the Company issued 23,502 125 14.375
Non-current assets right-of-use (“ROU”)	Non-current assets right-of-use (“ROU”) Upon commencement of a contract containing a lease, the Company classifies leases other than short-term leases as either an operating lease or a finance lease according to the criteria prescribed by ASC 842. The Company recognizes both lease liabilities and ROU assets on the balance sheet for all leases, except for short-term leases (those with a lease term of 12 months or less). Lease liabilities are initially measured at the present value of the future lease payments over the lease term, discounted at the rate implicit in the lease or, if that rate is not readily determinable, the Company’s incremental borrowing rate. The ROU assets represent the lessee’s right to use the underlying asset for the lease term and are initially measured at the same amount as the corresponding lease liability. For finance leases, the Company recognizes interest expense on the lease liability and amortization expense on the ROU asset. For operating leases, lease expense is recognized on a straight-line basis over the lease term. In February 2022, the Company entered into a four-year (i.e., 48-month) lease of an automobile, with an ending date of January 2026. The “base” annual lease payment is € 13,967 1,164 lease payment will remain fixed for the four (4) years For the initial measurement, the calculation of the net present value of the ROU asset and liability was made by using the discounted rate of 6.25 49,320 21,004 13,023 7,981
Fixed Assets	Fixed Assets Property and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted by the corresponding accumulated depreciation. Depreciation is systematically recorded in the consolidated financial statements by taking into consideration the use, purpose, and financial-technical duration of the assets, based on their estimated useful economic lives. Leasehold improvement depreciation is recorded based on the shorter of: (i) the life of the leasehold improvement; or, (ii) the remaining term of the lease. Ordinary maintenance costs are expensed to the Consolidated Statements of Operations and Comprehensive Loss in the year in which they are incurred. Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it, and/or to increase its productivity or safety for the purpose of economic productivity of the Company, are attributed to the asset to which they refer and depreciated based on its estimated useful economic life. Amortization of leasehold improvements is computed using the straight-line method based on the terms of the applicable lease or estimated useful life of the improvements, whichever is less.
Impairment of long-lived assets	Impairment of long-lived assets In accordance with ASC Topic 360-10-20, ‘‘Property, Plant and Equipment,” the Company performs an impairment test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired. Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. To date, no impairments have been identified for the six months ended June 30, 2024, and June 30, 2023.
Deferred offering costs	Deferred offering costs Deferred offering costs, which primarily consist of direct, incremental legal and accounting fees relating to fundraising activities (e.g., an IPO or other fundraising activities), are capitalized within prepaid expenses and other current assets before the offering and netted or offset with the offering proceeds upon closing of the offering. For the six months ended June 30, 2024, the Company incurred approximately € 0.2 For the six months ended June 30, 2023, the Company incurred approximately € 0.3
Recently issued accounting pronouncements	Recently issued accounting pronouncements In November 2023, the FASB issued ASU 2023-07 which amends ASC 280 to improve the information that a public entity discloses about its reportable segments and to address investor requests for more information about reportable segment expenses by requiring incremental disclosures for segment reporting. The effective date for ASU 2023-07 is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The amendment requires companies to disclose more information about their reportable segments, including: (1) (2) (3) (4) (5) In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which modifies the rules on income tax disclosures to require disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The guidance is effective for annual periods beginning after December 15, 2024, with early adoption permitted. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. In March 2024, the FASB issued ASU 2024-01, Scope Application of Profits Interest and Similar Awards, which clarifies how an entity determines whether a profits interest or similar award (hereafter a “profits interest award”) is (1) within the scope of Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation, or (2) not a share-based payment arrangement and therefore within the scope of other guidance. For public business entities, ASU 2024-01 is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim periods within those annual periods. The Company currently expects that this ASU will not have a material impact on its consolidated financial statements.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of cash and cash equivalents	Schedule of cash and cash equivalents At June 30, At December 31, 2024 2023 (Unaudited) Cash in bank € 3,945,143 € 3,687,402 Cash in short-term marketable securities 2,238,823 - Cash in hand & prepaid cards 4,000 4,018 Total cash and cash equivalents € 6,187,966 € 3,691,420
Schedule of fair values due to short-term nature of assets and liabilities	The carrying values of the Company’s research and development (“R&D”) tax credits, VAT credits, accounts payable, accrued expenses and other current liabilities were evaluated and determined to approximate their fair values due to the short-term nature of these assets and liabilities. Schedule of fair values due to short-term nature of assets and liabilities Total Level 1 Level 2 Level 3 June 30, 2024 Total Level 1 Level 2 Level 3 Cash and cash equivalents € 6,187,966 6,187,966 € - € - Marketable securities 10,718,210 10,718,210 - - Total cash and cash equivalents and marketable securities € 16,906,176 € 16,906,176 € - € - Total Level 1 Level 2 Level 3 December 31, 2023 Total Level 1 Level 2 Level 3 Cash and cash equivalents 3,691,420 3,691,420 Marketable Securities € 15,084,284 15,084,284 € - € - Total cash and cash equivalents and marketable securities € 18,775,704 € 18,775,704 € - € -

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	6 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consist of the following: Schedule of prepaid expenses and other current assets At June 30, At December 31, 2024 2023 (in Euros) (Unaudited) Value added tax (VAT) € 420,366 € 1,170,634 Research and development tax credit 766,680 833,000 Advances payments to suppliers 34,439 34,108 Other current assets 247,946 64,664 Other prepaids 193,866 378,148 Total € 1,663,297 € 2,480,554

Fixed assets, net (Tables)

Fixed assets, net (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of fixed assets,net	Fixed assets consist of the following: Schedule of fixed assets,net At June 30, At December 31, 2024 2023 (Unaudited) Software (ERP Implementation) € 87,800 € 87,800 Computers 37,840 35,971 Furniture and fixtures 13,005 13,005 Total fixed assets 138,645 136,776 Less: accumulated depreciation (75,931 ) (53,799 ) Fixed assets, net € 62,714 € 82,977

Other non-current assets (Table

Other non-current assets (Tables)	6 Months Ended
	Jun. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of other non-current assets	Other non-current assets consist of the following: Schedule of other non-current assets At June 30, At December 31, 2024 2023 (Unaudited) Value added tax (VAT) 110,774 € 630,342 Research and development tax credit 249,892 167,000 Other non-current assets 21,004 207,218 Total € 381,670 € 1,004,560

Share-based compensation (Table

Share-based compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Outstanding Stock Options	Schedule of Outstanding Stock Options Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of January 1, 2023 540,523 € 4.99 7.3 € 272,480 Granted 46,400 5.30 9.17 - Vested and exercised - - - - Cancelled or forfeited - - - - Outstanding as of December 31, 2023 586,923 € 4.84 6.53 € 67,596 Exercisable as of December 31, 2023 382,785 € 5.11 5.44 € 33,796 Outstanding, expected to vest as of December 31, 2023 204,138 € 4.34 8.58 € 33,800 Outstanding as of January 1, 2024 586,923 € 4.84 6.53 € 67,596 Granted - - - - Vested and exercised - - - - Cancelled or forfeited (147,783 ) - - - Outstanding as of June 30, 2024 439,140 € 4.53 8.12 € - Exercisable as of June 30, 2024 280,033 € 4.58 8.16 € - Outstanding, expected to vest as of June 30, 2024 159,107 € 4.44 8.05 € -
Schedule of share based compensation expenses	The Company’s share-based compensation expense for the period ended June 30, 2024 and June 30, 2023 is represented by the following table: Schedule of share based compensation expenses 2024 2023 Six Months Ended June 30, 2024 2023 Research & development expense € 37,173 € 36,718 Research & development expense - related party - - General & administrative expense 114,219 298,333 General & administrative expense- related party 81,376 80,381 Total € 232,768 € 415,433 Unrecognized expense € 747,043 € 1,471,743

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	Schedule of Accumulated Other Comprehensive Income Unrealized gains and losses on available-for-sale debt securities Foreign Currency Translation Adjustments Total Changes in Accumulated Other Comprehensive Income For the Period Ending June 30, 2024 Unrealized gains and losses on available-for-sale debt securities Foreign Currency Translation Adjustments Total Beginning Balance € 214,984 € 16,158 € 231,142 Adjustment for net gain on marketable securities (190,228 ) (190,228 ) Change in fair value of marketable securities 125,940 125,940 Cumulative translation adjustment - (16,081 ) (16,081 ) Total € 150,696 € 77 € 150,773

Related parties (Tables)

Related parties (Tables)	6 Months Ended
	Jun. 30, 2024
Schedule of accounts payable to related parties	The Company’s accounts payable to related parties are comprised as follows: Schedule of accounts payable to related parties At June 30, At December 31, 2024 2023 (Unaudited) San Raffaele Hospital € 189,762 € 170,888
Schedule of accrued expenses to related parties	The Company’s accrued expenses to related parties are comprised as follows: Schedule of accrued expenses to related parties At June 30, At December 31, 2024 2023 (Unaudited) San Raffaele Hospital € 34,306 € 413,935 Pierluigi Paracchi 252,000 175,254 Richard Slansky 176,812 116,738 Carlo Russo 235,750 155,651 Total € 698,868 € 861,578
Research and Development Expense [Member]
Schedule of third party and general and administrative expenses	The Company’s R&D Schedule of third party and related party expenses Six Months Ended June 30, 2024 Third Parties Related Parties Total Consultants & other third parties € 113,498 € 303,298 € 416,796 Materials & supplies 911,246 - 911,246 Compensation (including share-based) 349,839 329,227 679,066 Travel & entertainment 17,589 - 17,589 Other 15,693 - 15,693 Total € 1,407,865 € 632,525 € 2,040,390 Six Months Ended June 30, 2023 Third Parties Related Parties Total (Unaudited) Consultants & other third parties € 150,402 € 72,500 € 222,902 Materials & supplies 2,464,107 660,863 3,124,970 Compensation (including share-based) 212,003 330,796 542,799 Travel & entertainment 27,892 - 27,892 Other 3,239 - 3,239 Total € 2,857,643 € 1,064,159 € 3,921,802
General and Administrative Expense [Member]
Schedule of third party and general and administrative expenses	The Company’s general and administrative expenses are also a combination of third-party and related-party expenses, as detailed below: Schedule of third party and general and administrative expenses Six Months Ended June 30, 2024 Third Parties Related Parties Total Compensation (including share-based) € 451,903 € 698,620 € 1,150,523 Accounting, legal & other professional 557,049 - 557,049 Communication & IT related facility 85,277 85,277 Facility & insurance related 984 8,120 9,104 Consultants & other third parties 324,306 - 324,306 Other 350,752 967 351,719 Total € 1,770,271 € 707,707 € 2,477,978 Six Months Ended June 30, 2023 Third Parties Related Parties Total (Unaudited) Compensation (including share-based) € 697,228 € 673,795 € 1,371,023 Accounting, legal & other professional 720,989 - 720,989 Communication & IT related facility - - - Facility & insurance related 2,868 8,171 11,039 Consultants & other third parties 314,059 - 314,059 Other 460,320 943 461,263 Total € 2,195,464 € 682,909 € 2,878,373

Commitments and contingencies (

Commitments and contingencies (Tables)	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of company obligations by contractual maturity	The following table summarizes the Company’s obligations by contractual maturity on June 30, 2024: Schedule of company obligations by contractual maturity Payments by Period Total Less than a year 1 to 3 years 4 to 5 years More than 5 years OSR operating leases and office rent € 21,267 € 15,012 € 6,255 € - € - OSR- ARLA 166,700 166,700 - - - AGC manufacturing 75,985 75,985 - - - Insurance policies 11,095 6,996 4,099 - - Total € 275,047 € 264,693 € 10,354 € - € -

Nature of business and history

Nature of business and history (Details Narrative)						1 Months Ended				6 Months Ended
	Apr. 26, 2024 USD ($)	May 12, 2023 USD ($)	Dec. 27, 2021 shares	Dec. 15, 2021 EUR (€) shares	May 20, 2021 shares	Mar. 31, 2024 USD ($) shares	Mar. 31, 2024 EUR (€) shares	Jul. 31, 2023 USD ($) shares	Jul. 31, 2023 EUR (€) shares	Jun. 30, 2024 EUR (€) shares	Dec. 31, 2023 EUR (€) shares	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 shares	Dec. 31, 2021 shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Conversion of stock, shares issued					15,000,000
Common Stock, Shares Subscribed but Unissued				720,114
[custom:AmericanDepositoryShares]				2,400,000
Common stock, shares outstanding										18,289,866	18,216,958		18,216,858	18,216,858
[custom:NetListingCosts-0] | €				€ 3,900,000
Gross sale proceeds | $		$ 100,000,000
Net Income (Loss) Attributable to Parent | €										€ 4,038,506	€ 4,886,230	€ 6,759,225
Retained Earnings (Accumulated Deficit) | €										51,181,531	47,143,025
Cash | €										6,187,966	€ 3,691,420
Marketable securities | €										10,700,000
Unrealized net loss from exchange rate | €										€ 200,000
Prior Sales Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares outstanding						18,289,866	18,289,866	18,216,958	18,216,958
Current Sales Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate offering price | $	$ 16,362,816
American Depository Shares [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued						72,908	72,908	100	100
Shares issued value						$ 293,328	€ 270,885	$ 582	€ 531
IPO [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues				3,120,114
[custom:NetListingCosts-0] | €				€ 29,000,000
Over-Allotment Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
[custom:AmericanDepositoryShares]			96,744

Schedule of cash and cash equiv

Schedule of cash and cash equivalents (Details) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Cash in bank	€ 3,945,143	€ 3,687,402
Cash in short-term marketable securities	2,238,823
Cash in hand & prepaid cards	4,000	4,018
Total cash and cash equivalents	€ 6,187,966	€ 3,691,420

Schedule of fair values due to

Schedule of fair values due to short-term nature of assets and liabilities (Details) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Platform Operator, Crypto Asset [Line Items]
Cash and cash equivalents	€ 6,187,966	€ 3,691,420
Marketable Securities	10,718,210	15,084,284
Total cash and cash equivalents and marketable securities	16,906,176	18,775,704
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash and cash equivalents	6,187,966	3,691,420
Marketable Securities	10,718,210	15,084,284
Total cash and cash equivalents and marketable securities	16,906,176	18,775,704
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash and cash equivalents
Marketable Securities
Total cash and cash equivalents and marketable securities
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Cash and cash equivalents
Marketable Securities
Total cash and cash equivalents and marketable securities

Summary of significant accoun_4

Summary of significant accounting policies (Details Narrative)				1 Months Ended	6 Months Ended
	Apr. 30, 2024 shares	Dec. 15, 2021 shares	May 20, 2021 shares	Jun. 30, 2023 shares	Jun. 30, 2024 EUR (€) shares	Dec. 31, 2023 EUR (€) shares	Jun. 30, 2023 EUR (€) shares	Jun. 30, 2024 $ / shares	Jun. 30, 2024 EUR (€) shares	Mar. 31, 2024 shares	Jul. 31, 2023 shares	Jan. 01, 2023 shares	Dec. 31, 2022 shares	Dec. 31, 2021 shares
Property, Plant and Equipment [Line Items]
Net loss | €					€ 4,038,506	€ 4,886,230	€ 6,759,225
Comprehensive loss | €					4,118,875		6,759,225
Common Stock, Shares Authorized						59,700,000			59,700,000
Common Stock, Shares, Outstanding						18,216,958			18,289,866				18,216,858	18,216,858
Common Stock, Capital Shares Reserved for Future Issuance						1,800,000			1,800,000
Number of options shares outstanding						586,923			439,140			540,523	540,523
Net exchange gain | €					153,791		(152,041)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | €					4,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period				10 years
Number of shares available for issuance						1,234,772			1,389,846			1,281,162
Annual lease payment | €					13,967
Annual lease payment | €					€ 1,164
Lease, description					lease payment will remain fixed for the four (4) years
Operating lease discount rate									6.25%
Operating lease liability | €					€ 49,320
Net present value of right of use asset and liability | €									€ 21,004
Lease liability current | €									13,023
Long-term liability | €									€ 7,981
IPO [Member]
Property, Plant and Equipment [Line Items]
Number of warrants issued to the underwriters		3,120,114
ATM Offering Costs [Member]
Property, Plant and Equipment [Line Items]
Number of stock issued, value | €					200,000		€ 300,000
Maximum [Member]
Property, Plant and Equipment [Line Items]
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | €					€ 5,000,000
Underswriters Common Share Warrants [Member]
Property, Plant and Equipment [Line Items]
Underwriters ordinary shares, warrants					23,502		23,502
Share-Based Payment Arrangement, Option [Member]
Property, Plant and Equipment [Line Items]
Number of options shares outstanding				318,459			318,459		280,033
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	147,783
Underswriters Common Share Warrants [Member]
Property, Plant and Equipment [Line Items]
Number of options shares outstanding				23,502			23,502
Underswriters Warrants [Member] | IPO [Member]
Property, Plant and Equipment [Line Items]
Number of warrants issued to the underwriters					23,502
Exercisable percentage of warrant									125%
Exercise price | $ / shares								$ 14.375
American Depository Shares [Member]
Property, Plant and Equipment [Line Items]
Shares, Issued										72,908	100
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Net loss | €
Number of shares outstanding				18,216,858		18,216,958	18,216,858		18,289,866				18,216,858
Common Stock [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Share-based payment award, options, number of shares, period increase			2,700,000
Number of shares available for issuance			2,700,000
Number of shares outstanding									27,000,000
Common Stock [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Number of shares available for issuance			1,828,986
Common Stock [Member] | Share-Based Payment Arrangement, Option [Member]
Property, Plant and Equipment [Line Items]
Number of options shares outstanding									18,289,866
Number of shares authorized									1,828,986
Number of shares outstanding, percentage					10%

Income taxes (Details Narrative

Income taxes (Details Narrative)	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Percentage of taxable income can off-set	80%

Schedule of prepaid expenses an

Schedule of prepaid expenses and other current assets (Details) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Value added tax (VAT)	€ 420,366	€ 1,170,634
Research and development tax credit	766,680	833,000
Advances payments to suppliers	34,439	34,108
Other current assets	247,946	64,664
Other prepaids	193,866	378,148
Total	€ 1,663,297	€ 2,480,554

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details Narrative) - EUR (€)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Percentage of value added tax	22%		22%
Value added tax refund received	€ 1,700,000
Value added tax refund received short-term	1,300,000
Value added tax refund received long-term	400,000
Research and development tax credit	4,000,000
Amount utilized to offset social contributions and taxes payable	400,000	€ 400,000
Research and development expense	2,040,390	3,921,802
Other Assets, Current	247,946		€ 64,664
Other Prepaid Expense, Current	193,866		€ 378,148
Director [Member]
Other Prepaid Expense, Current	100,000	200,000
Allowance For Corporate Equity [Member]
Other Assets, Current	200,000
Allowance For Corporate Equity [Member] | Revision of Prior Period, Reclassification, Adjustment [Member]
Other Assets, Current	180,000
Financial Claims For Accrued Interest On Ongoing Investments [Member]
Other Assets, Current	53,000
Research and Development Expense Related Party [Member]
Research and development expense	€ 400,000	€ 400,000

Schedule of fixed assets,net (D

Schedule of fixed assets,net (Details) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Software (ERP Implementation)	€ 87,800	€ 87,800
Computers	37,840	35,971
Furniture and fixtures	13,005	13,005
Total fixed assets	138,645	136,776
Less: accumulated depreciation	(75,931)	(53,799)
Fixed assets, net	€ 62,714	€ 82,977

Fixed assets, net (Details Narr

Fixed assets, net (Details Narrative) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Net of accumulated depreciation	€ 87,800	€ 87,800
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Net of accumulated depreciation	€ 87,800		€ 87,800

Schedule of other non-current a

Schedule of other non-current assets (Details) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Research and development tax credit	€ 250,000	€ 167,000
Nonrelated Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Value added tax (VAT)	110,774	630,342
Research and development tax credit	249,892	167,000
Other non-current assets	21,004	207,218
Total	€ 381,670	€ 1,004,560

Other non-current assets (Detai

Other non-current assets (Details Narrative) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
VAT credit outstanding	€ 420,366	€ 1,170,634
Research and development tax credit	250,000	€ 167,000
Revision of Prior Period, Reclassification, Adjustment [Member]
Other non current assets	180,000
Other Current Assets [Member]
Right of use of asset	€ 21,004

Retirement benefit obligation (

Retirement benefit obligation (Details Narrative) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Retirement Benefits [Abstract]
Description of annual contributions	The annual accrual is approximately 7% of total pay, with no ceiling, and is revalued each year by applying a pre-established rate of return of 1.50%, plus 75% of the Consumer Price Index
Percentage of total pay		7%
Obligation amount	€ 196,368	€ 164,655

Shareholders_ equity (Details N

Shareholders’ equity (Details Narrative)	1 Months Ended				6 Months Ended
	Mar. 31, 2024 USD ($) shares	Mar. 31, 2024 EUR (€) shares	Jul. 31, 2023 USD ($) shares	Jul. 31, 2023 EUR (€) shares	Jun. 30, 2024 EUR (€) shares	Dec. 31, 2023 EUR (€) shares	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 shares	Dec. 31, 2021 shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares outstanding					18,289,866	18,216,958		18,216,858	18,216,858
Fair value of options granted | €					€ 232,768	€ 324,451	€ 415,433
Common stock, shares issued					18,289,866	18,216,958
Ordinary shares reserved					1,800,000	1,800,000
American Depository Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued	72,908	72,908	100	100
Shares issued value	$ 293,328	€ 270,885	$ 582	€ 531

Schedule of Outstanding Stock O

Schedule of Outstanding Stock Options (Details) - EUR (€)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Number of options outstanding, Beginning	586,923	540,523
Weighted average exercise price outstanding, Beginning	€ 4.84	€ 4.99
Weighted average remaining contractual term outstanding	8 years 1 month 13 days	6 years 6 months 10 days	7 years 3 months 18 days
Aggregate intrinsic value outstanding, Beginning	€ 67,596	€ 272,480
Number of options, Granted		46,400
Weighted average exercise price, Granted		€ 5.30
Weighted average remaining contractual term, Granted		9 years 2 months 1 day
Aggregate intrinsic value , Granted
Number of options, Vested and exercised
Weighted average exercise price, Vested and exercised
Aggregate intrinsic value, Vested and exercised
Number of options, Cancelled or forfeited	147,783
Weighted average exercise price, Cancelled or forfeited
Aggregate intrinsic value, Cancelled or forfeited
Number of options outstanding, Ending	439,140	586,923	540,523
Weighted average exercise price outstanding, Ending	€ 4.53	€ 4.84	€ 4.99
Aggregate intrinsic value outstanding,Ending		€ 67,596	€ 272,480
Number of options,Exercisable	280,033	382,785
Weighted average exercise price, Exercisable	€ 4.58	€ 5.11
Weighted average remaining contractual term, Exercisable	8 years 1 month 28 days	5 years 5 months 8 days
Aggregate intrinsic value, Exercisable		€ 33,796
Number of options outstanding, Expected to vest	159,107	204,138
Weighted average exercise price outstanding, Expected to vest	€ 4.44	€ 4.34
Weighted average remaining contractual term (years) Outstanding expected to vest	8 years 18 days	8 years 6 months 29 days
Aggregate intrinsic value outstanding, Expected to vest		€ 33,800
Number of options, Cancelled or forfeited	(147,783)

Schedule of share based compens

Schedule of share based compensation expenses (Details) - EUR (€)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	€ 232,768	€ 415,433
Unrecognized expense	747,043	1,471,743
Research and Development Expense [Member] | Nonrelated Party [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	37,173	36,718
Research and Development Expense [Member] | Related Party [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total
General and Administrative Expense [Member] | Nonrelated Party [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	114,219	298,333
General and Administrative Expense [Member] | Related Party [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	€ 81,376	€ 80,381

Share-based compensation (Detai

Share-based compensation (Details Narrative)	1 Months Ended		6 Months Ended			12 Months Ended
	Apr. 30, 2024 shares	Mar. 31, 2023 $ / shares shares	Jun. 30, 2024 EUR (€) € / shares shares	Dec. 31, 2023 EUR (€) € / shares shares	Jun. 30, 2023 EUR (€) € / shares shares	Dec. 31, 2023 € / shares shares	Jan. 01, 2023 shares	Dec. 31, 2022 shares
Number of options granted			439,140	586,923		586,923	540,523	540,523
Number of options available for grant			1,389,846	1,234,772		1,234,772	1,281,162
Number of stock options awarded						46,400
Number of shares expired	147,783
Fair value of options granted | €			€ 232,768	€ 324,451	€ 415,433
Unrecognized expense | €			747,043		€ 1,471,743
Weighted average fair value | €			€ 0
Weighted average fair value of options granted | € / shares			€ 5.30
Weighted average shares			18,256,622		18,216,858
Common stock par value | € / shares			€ 0	€ 0	€ 0	€ 0
Director [Member]
Number of stock options awarded		46,400
Exercise price per share | $ / shares		$ 5.62

Schedule of Accumulated Other C

Schedule of Accumulated Other Comprehensive Income (Details)	6 Months Ended
	Jun. 30, 2024 EUR (€)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	€ 231,142
Adjustment for net gain on marketable securities	(190,228)
Change in fair value of marketable securities	125,940
Cumulative translation adjustment	(16,081)
Total	150,773
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	214,984
Adjustment for net gain on marketable securities	(190,228)
Change in fair value of marketable securities	125,940
Cumulative translation adjustment
Total	150,696
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	16,158
Cumulative translation adjustment	(16,081)
Total	€ 77

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details Narrative) € in Millions	6 Months Ended
	Jun. 30, 2024 EUR (€)
Equity [Abstract]
Realized gain on investing activities	€ 0.2
Unrealized gain on marketable securities	€ 0.1

Schedule of third party and rel

Schedule of third party and related party expenses (Details) - EUR (€)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Related Party Transaction [Line Items]
Total	€ 2,040,390	€ 3,921,802
Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	416,796	222,902
Materials And Supplies [Member]
Related Party Transaction [Line Items]
Total	911,246	3,124,970
Compensation [Member]
Related Party Transaction [Line Items]
Total	679,066	542,799
Travel And Entertainment [Member]
Related Party Transaction [Line Items]
Total	17,589	27,892
Other [Member]
Related Party Transaction [Line Items]
Total	15,693	3,239
Third Parties [Member]
Related Party Transaction [Line Items]
Total	1,407,865	2,857,643
Third Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	113,498	150,402
Third Parties [Member] | Materials And Supplies [Member]
Related Party Transaction [Line Items]
Total	911,246	2,464,107
Third Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	349,839	212,003
Third Parties [Member] | Travel And Entertainment [Member]
Related Party Transaction [Line Items]
Total	17,589	27,892
Third Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total	15,693	3,239
Related Parties [Member]
Related Party Transaction [Line Items]
Total	632,525	1,064,159
Related Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	303,298	72,500
Related Parties [Member] | Materials And Supplies [Member]
Related Party Transaction [Line Items]
Total		660,863
Related Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	329,227	330,796
Related Parties [Member] | Travel And Entertainment [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total

Schedule of third party and gen

Schedule of third party and general and administrative expenses (Details) - EUR (€)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Related Party Transaction [Line Items]
Total	€ 2,477,978	€ 2,878,373
Compensation [Member]
Related Party Transaction [Line Items]
Total	1,150,523	1,371,023
Accounting Legal and Other Professional [Member]
Related Party Transaction [Line Items]
Total	557,049	720,989
Communication and IT Related [Member]
Related Party Transaction [Line Items]
Total	85,277
Facility and Insurance Related [Member]
Related Party Transaction [Line Items]
Total	9,104	11,039
Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	324,306	314,059
Other [Member]
Related Party Transaction [Line Items]
Total	351,719	461,263
Third Parties [Member]
Related Party Transaction [Line Items]
Total	1,770,271	2,195,464
Third Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	451,903	697,228
Third Parties [Member] | Accounting Legal and Other Professional [Member]
Related Party Transaction [Line Items]
Total	557,049	720,989
Third Parties [Member] | Communication and IT Related [Member]
Related Party Transaction [Line Items]
Total	85,277
Third Parties [Member] | Facility and Insurance Related [Member]
Related Party Transaction [Line Items]
Total	984	2,868
Third Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total	324,306	314,059
Third Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total	350,752	460,320
Related Parties [Member]
Related Party Transaction [Line Items]
Total	707,707	682,909
Related Parties [Member] | Compensation [Member]
Related Party Transaction [Line Items]
Total	698,620	673,795
Related Parties [Member] | Accounting Legal and Other Professional [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Communication and IT Related [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Facility and Insurance Related [Member]
Related Party Transaction [Line Items]
Total	8,120	8,171
Related Parties [Member] | Consultants and Other Third Parties [Member]
Related Party Transaction [Line Items]
Total
Related Parties [Member] | Other [Member]
Related Party Transaction [Line Items]
Total	€ 967	€ 943

Schedule of accounts payable to

Schedule of accounts payable to related parties (Details) - Related Party [Member] - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
San Raffaele Hospital	€ 189,762	€ 170,888
San Raffaele Hospital [Member]
Related Party Transaction [Line Items]
San Raffaele Hospital	€ 189,762	€ 170,888

Schedule of accrued expenses to

Schedule of accrued expenses to related parties (Details) - EUR (€)	Jun. 30, 2024	Dec. 31, 2023
Related Party Transaction [Line Items]
Total	€ 698,868	€ 861,578
San Raffaele Hospital [Member]
Related Party Transaction [Line Items]
Total	34,306	413,935
Pierluigi Paracchi [Member]
Related Party Transaction [Line Items]
Total	252,000	175,254
Richard Slansky [Member]
Related Party Transaction [Line Items]
Total	176,812	116,738
Carlo Russo [Member]
Related Party Transaction [Line Items]
Total	€ 235,750	€ 155,651

Related parties (Details Narrat

Related parties (Details Narrative)		1 Months Ended		6 Months Ended
	Apr. 20, 2023 EUR (€)	Feb. 28, 2024 EUR (€)	Feb. 28, 2022 EUR (€)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 EUR (€)	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 EUR (€)	Dec. 31, 2023 EUR (€)	Mar. 31, 2023 EUR (€)
First Indication [Member]
Related Party Transaction [Line Items]
Future option fees					€ 1,000,000
Second Indication [Member]
Related Party Transaction [Line Items]
Future option fees					500,000
Third Indication [Member]
Related Party Transaction [Line Items]
Future option fees					300,000
Amended and Restated OSR License Agreement [Member]
Related Party Transaction [Line Items]
Upfront fee					€ 250,000
Commitments, description				The Company is also obligated to carry out its development activities using qualified and experienced professionals and sufficient level of resources. In particular, consistent with the terms of the Original OSR License Agreement, the ARLA continues to require the Company to invest (a) at least €5,425,000 with respect to the development of the licensed products, and (b) at least €2,420,000 with respect to the manufacturing of such licensed products (subject to certain adjustments).	The Company is also obligated to carry out its development activities using qualified and experienced professionals and sufficient level of resources. In particular, consistent with the terms of the Original OSR License Agreement, the ARLA continues to require the Company to invest (a) at least €5,425,000 with respect to the development of the licensed products, and (b) at least €2,420,000 with respect to the manufacturing of such licensed products (subject to certain adjustments).
Sublicense Agreement [Member]
Related Party Transaction [Line Items]
License fees	€ 875,000
Amendment to OSR Amendedand Restated License Agreement [Member]
Related Party Transaction [Line Items]
Agreement fee					€ 400,000
Total project amounting					200,000
Amendment to OSR Amendedand Restated License Agreement [Member] | First Solid Cancer Indication Option Fee [Member]
Related Party Transaction [Line Items]
Cumulative expense					11,000,000
Amendment to OSR Amendedand Restated License Agreement [Member] | Second Solid Cancer Indication Option Fee [Member]
Related Party Transaction [Line Items]
Option fee					1,000,000
Related Party [Member] | OSR Sponsor Research Agreement [Member]
Related Party Transaction [Line Items]
Payment for research agreement					300,000
Pierluigi Paracchi [Member]
Related Party Transaction [Line Items]
Salary and Wage, Excluding Cost of Good and Service Sold			€ 420,000
Percentage of annual bonus			40%
Accrued bonus									€ 112,000
Director [Member] | Pierluigi Paracchi [Member]
Related Party Transaction [Line Items]
Gross bonus					84,000	€ 84,000		€ 168,000
Employee benefits and share based compensation					300,000	300,000
Naldini [Member]
Related Party Transaction [Line Items]
Employee benefits and share based compensation					50,000
Annual fee							€ 100,000
Dr.Gentner [[Member]
Related Party Transaction [Line Items]
Employee benefits and share based compensation					22,500
Annual fee							€ 45,000
Dr.Gentner [[Member] | Consulting Agreement [Member]
Related Party Transaction [Line Items]
Employee benefits and share based compensation					€ 5,000
Annual fee		€ 15,000
Dr. Carlo Russo [Member]
Related Party Transaction [Line Items]
Percentage of annual bonus				30%	30%
Gross salary | $				$ 500,000
Dr. Russo [Member]
Related Party Transaction [Line Items]
Accrued bonus					€ 70,000	84,000		156,000	€ 112,000
Dr. Russo [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Interest expense					€ 329,000	331,000
Richard Slansky [Member]
Related Party Transaction [Line Items]
Percentage of annual bonus				30%	30%
Accrued bonus					€ 53,000	63,000		€ 116,000
Richard Slansky [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Gross annual compensation | $				$ 375,000
Richard Slansky [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Interest expense					€ 243,000	€ 253,000

Schedule of company obligations

Schedule of company obligations by contractual maturity (Details)	Jun. 30, 2024 EUR (€)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	€ 275,047
Less than a year	264,693
1 to 3 years	10,354
4 to 5 years
More than 5 years
OSR [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	21,267
OSR Operating Leases And Office Rent [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Less than a year	15,012
1 to 3 years	6,255
4 to 5 years
More than 5 years
OSR Amended And Restated Licenset Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	166,700
Less than a year	166,700
1 to 3 years
4 to 5 years
More than 5 years
AGC Manufacturing [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	75,985
Less than a year	75,985
1 to 3 years
4 to 5 years
More than 5 years
Insurance Policy [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	11,095
Less than a year	6,996
1 to 3 years	4,099
4 to 5 years
More than 5 years

Commitments and contingencies_2

Commitments and contingencies (Details Narrative) - EUR (€)		1 Months Ended		6 Months Ended		12 Months Ended
	Feb. 11, 2022	Jan. 31, 2024	Feb. 28, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Investment Owned, Balance, Principal Amount				€ 5,425,000
Raw material costs				300,000
Annual rent amount				15,150
Minimum payments amount outstanding				7,575
Insurance expenses outstanding for payments related to automobile				€ 11,000
Minimum [Member]
Loss Contingencies [Line Items]
Royalty fees percentage				0.50%
Maximum [Member]
Loss Contingencies [Line Items]
Royalty fees percentage				1%
OSR [Member]
Loss Contingencies [Line Items]
Percentage of royalties				4%
San Raffaele Hospital [Member]
Loss Contingencies [Line Items]
Incurred expenses				€ 900,000	€ 1,600,000
Manufacturing cost				€ 10,100,000
Original OSR License Agreement [Member]
Loss Contingencies [Line Items]
Commitments, description				In particular, consistent with the terms of the Original OSR License Agreement, the ARLA continues to require the Company to invest (a) at least €5,425,000 with respect to the development of the licensed products, and (b) at least €2,420,000 with respect to the manufacturing of such licensed products (subject to certain adjustments).
AGC Biologics Agreement [Member]
Loss Contingencies [Line Items]
Potential milestone				€ 300,000
Technology transfer fee				500,000
AGC Agreement [Member]
Loss Contingencies [Line Items]
Manufacturing cost				1,000,000
Process Transfer Agreement [Member]
Loss Contingencies [Line Items]
Raw materials							€ 405,000
Raw materials handling							40,500
Raw material costs							€ 24,000
Master Service Agreement [Member]
Loss Contingencies [Line Items]
Raw material costs			€ 1,500,000	200,000
Raw material and third party costs			€ 700,000
Production cost				€ 300,000		€ 200,000
Process Transfer Agreement Agreement [Member]
Loss Contingencies [Line Items]
Production cost		€ 8,000
Lease Agreement [Member]
Loss Contingencies [Line Items]
Finance lease agreement amount	€ 27,985

Subsequent events (Details Narr

Subsequent events (Details Narrative) - Subsequent Event [Member] - EUR (€)	1 Months Ended
	Oct. 31, 2024	Sep. 30, 2024	Jul. 31, 2024
Subsequent Event [Line Items]
Non qualified stock options			577,884
Stock option exercise price			€ 3.083
Director [Member]
Subsequent Event [Line Items]
Non qualified stock options term vest term			10 years
Officers And Employees [Member] | Minimum [Member]
Subsequent Event [Line Items]
Non qualified stock options term vest term			10 years
Officers And Employees [Member] | Maximum [Member]
Subsequent Event [Line Items]
Non qualified stock options term vest term			3 years
AGC Biologics SPA [Member]
Subsequent Event [Line Items]
Production cost	€ 100,000	€ 159,000	€ 100,000
cancellation fees			€ 112,000